1. A method of treating cachexia in a human subject, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a quantity of Ab to IL-1α effective to reduce at least one cachexia symptom in the subject. A method according to claim 1, characterized in that Ab to IL-1α is mAb. 3. The method of claim 2, wherein the mAb is IgGl. 4. The method of claim 2, wherein the mAb comprises a complementarity determining portion of MABpl. 5. The method of claim 2, wherein the mAb is MABpl. 6. A method according to claim 1, characterized in that the dry body weight of the subject increases after administration of the pharmaceutical composition. A method according to claim 1, characterized in that the body weight of the subject increases after administration of the pharmaceutical composition. The method of claim 1, wherein the subject's appetite improves after administration of the pharmaceutical composition. The method according to claim 1, characterized in that the subject has cancer in the terminal stage. The method according to claim 1, characterized in that the muscle mass of the subject increases after administration of the pharmaceutical composition. A method according to claim 1, characterized in that the dry body weight of the subject increases after administration of the pharmaceutical composition. A method for increasing the lifespan of a cachexia mammalian subject, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a certain amount of Ab to IL-1α effective to increase the lifespan of the subject by at least 10% compared with the expected lifespan subject's life. 13. The method according to p. 12, characterized in that1. Способ лечения кахексии у субъекта-человека, причем способ включает этап введения субъекту фармацевтической композиции, содержащей фармацевтически приемлемый носитель и некоторо
